Page 10 of 11
9. Developing countries' medical needs unfulfilled by Big Pharma
'The world's biggest pharmaceutical firms have failed to develop two-thirds of the 139 urgently needed treatments in developing countries," Julia Kollewe reported for The Guardian in November 2018, according to a report by Access to Medicine Foundation, which "found that most firms focus on infectious diseases such as HIV/Aids, malaria and tuberculosis but had failed to focus on other serious ailments..... In particular, the foundation called for an infants' vaccine for cholera and a single-dose oral cure for syphilis."
It's not all bad news. "The foundation's report also highlighted 45 best and innovative practices that could 'help raise the level of standard practice' and 'achieve greater access to medicine,'" Project Censored noted. "The report highlights examples such as the development of a child-friendly chewable tablet for roundworm and whipworm, which infect an estimated 795 million people," The Guardian reported. "Johnson & Johnson has pledged to donate 200m doses a year until 2020." The possibilities underscore why attention is vital.
Attention makes a difference, Project Censored pointed out.
"In an effort to mobilize investors to pressure pharmaceutical companies to make more medicines available to developing countries, the foundation presented the findings of its reports to 81 global investors at events in London, New York, and Tokyo," Project Censored noted. "As of April 2019, Access to Medicine reported that, since the release of the 2018 Access to Medicine Index in November 2018, ninety major investors had pledged support of its research and signed its investor statement.
But attention has been sorely lacking in the corporate media. "With the exception of a November 2018 article by Reuters, news of the Access to Medicine Index's findings appear to have gone unreported in the corporate press," Project Censored concluded.